跳到正文
原文
STAT Pharma 医药频道· Ed Silverman·· 2026-10-20AI 评分50

分析显示2025年新药 launch net price 中位数升至25.7万美元

STAT+: Launch prices for new medicines dipped slightly last year but remain high, analysis finds

AI 导读

Institute for Clinical and Economic Review与West Health分析发现,2025年202款新药经通胀与折扣调整后净价格中位数升至257,000美元,较2022年的173,000美元上升35%。约四分之一的药物年度净价格超过50万美元,34%介于20万至50万美元之间;其中位标价(亦经通胀调整)上升24%至293,000美元。

正文

By Ed Silverman

Oct. 20, 2026

Pharmalot Columnist, Senior Writer

Amid ongoing angst over prescription drug prices, a new analysis found the median net price for 202 newly launched medicines, when adjusted for inflation and manufacturer discounts, rose by 35% to $257,000 last year, from $173,000 in 2022.

About one in four drugs launched in 2025 had an annual net price exceeding $500,000, while another 34% were priced between $200,000 and $500,000, according to the analysis by the Institute for Clinical and Economic Review, a nonprofit that assesses the value of medicines, and West Health, a nonprofit that advocates for lower health care costs.

Interestingly, the median list price for the drugs — also adjusted for inflation — rose 24% during that time, to $293,000. Normally, list prices are higher than net prices, since discounts are subtracted. The reasons for the divergence were not analyzed but indicate varying discounts for different types of drugs.

STAT+ Exclusive Story

Already have an account? Log in

STAT+

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

来源:STAT Pharma 医药频道 · statnews.com